Norwood Immunology: Temporary Suspension | Company Announcements

Friday 27 March, 2009

Norwood Immunology

Temporary Suspension

RNS Number : 5811P

Norwood Immunology Ld

27 March 2009

NORWOOD IMMUNOLOGY LIMITED

Temporary suspension of trading in securities

Norwood Immunology Limited and its subsidiaries ('Norwood Immunology' or the 'Group') (AIM:NIM), the Group focused on stem cell therapies, the rejuvenation and repair of the immune system and the development of virosomal vaccines, today announces that its AIM securities will today be suspended pursuant to the AIM Rules for Companies as Norwood Immunology will be unable to publish its interim report for the six months ended 31 December 2008 by 31 March 2009. This has been as a consequence of the proposed disposal of Bestewil Holdings B.V. and finalisation of the Group's Annual Report and Accounts for the year ended 30 June 2008 announced on 6 and 10 March 2009 respectively.

A further announcement will be made in due course.

For further information please contact:

Norwood Immunology Limited
Richard Williams, Chief Executive Officer	+44 (0)7860 295153

KBC Peel Hunt Ltd (NOMAD Adviser and Broker)	+44 (0)207 418 8900
Capel Irwin
David Anderson

This information is provided by RNS

The company news service from the London Stock Exchange

END

SUSPUUBAWUPBGRQ

Investegate takes no responsibility for the accuracy of the information within the site.

The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.